▶ 調査レポート

世界の化学発光イムノアッセイ(CLIA)市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Chemiluminescence Immunoassay (CLIA) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Mordor Intelligenceが調査・発行した産業分析レポートです。世界の化学発光イムノアッセイ(CLIA)市場2022年-2027年:成長・動向・新型コロナの影響・市場予測 / Chemiluminescence Immunoassay (CLIA) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) / MRC2203A175資料のイメージです。• レポートコード:MRC2203A175
• 出版社/出版日:Mordor Intelligence / 2022年1月
• レポート形態:英文、PDF、113ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥703,000 (USD4,750)▷ お問い合わせ
  Site Licence¥962,000 (USD6,500)▷ お問い合わせ
  Corporate License¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の本市場調査レポートでは、世界の化学発光イムノアッセイ(CLIA)市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品種類別(分析装置、試薬、消耗品)分析、用途別(腫瘍、自己免疫疾患、感染症、心血管疾患、内分泌障害)分析、エンドユーザー別(製薬・バイオテクノロジー企業、病院・臨床検査室、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の化学発光イムノアッセイ(CLIA)市場規模:製品種類別(分析装置、試薬、消耗品)
・世界の化学発光イムノアッセイ(CLIA)市場規模:用途別(腫瘍、自己免疫疾患、感染症、心血管疾患、内分泌障害)
・世界の化学発光イムノアッセイ(CLIA)市場規模:エンドユーザー別(製薬・バイオテクノロジー企業、病院・臨床検査室、その他)
・世界の化学発光イムノアッセイ(CLIA)市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(F.Hoffmann-La Roche AG、Mindray Medical International Limited、Siemens Healthcare GmbH、…)
・市場機会・将来傾向

The Chemiluminescence Immunoassay (CLIA) market is anticipated to grow with a CAGR of 6.6% during the forecast period. The major factors attributing to the growth of the chemiluminescence immunoassay (CLIA) market are the rising incidence of chronic diseases such as cardiovascular diseases, diabetes, autoimmune diseases, cancer, and others.

The rise in the population suffering from chronic diseases is propelling the market growth. Heart disease continues to remain the major cause of death in the United States. In 2018, as per the AHA statistics, around 720,000 Americans have experienced a coronary event and around 335,000 have experienced a recurrent event. And there are few more factors which are playing key roles in taking the chemiluminescence immunoassay (CLIA) market to the next level, among them one is on-going developments related to chemiluminescence analyzers and its technology which are expected to further drive the growth of global chemiluminescence immunoassay (CLIA) market.

Key Market Trends

Reagents Segment is Expected to Hold the Largest Market Share in the Chemiluminescence Immunoassay (CLIA) Market

The reagents segment is expected to continue its dominance during the forecast period, owing to the relatively higher frequency of reagent replacement when compared to analyzer systems.

As per the statistics from GLOBOCAN 2018, worldwide 18,078,957 individuals have cancer. Asia remains the leading contributor in the rising incidence of cancer with a reported share of 48.4% followed by Europe, North and Latin America, Africa, and Oceania with a share of 23.4%, 13.2%, and 7.8%, 5.8%, and 1.4% respectively.

Therefore there is an increasing demand for ultra-sensitive disease diagnosis, better accuracy, and quality, and rising development in new testing options that are expected to drive the reagents market. Increasing demand for high-content diagnosis and clinical research for cancer, cardiovascular, and other chronic diseases, in particular, is also strengthening the market growth of reagents.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall chemiluminescence immunoassay (CLIA) market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cardiovascular diseases and cancer and the revolution in test offerings is among the major factors.

In the North America region, the United States holds the largest market share owing to factors such as the increasing number of populations suffering from cardiovascular diseases and other chronic diseases. As per the CDC (Centers for Disease Control and Prevention) and AHA, coronary heart disease is the main cause of deaths in the US accompanied by stroke, high blood pressure, coronary disease, heart failure, and other CVD. However, the rising geriatric population and developments related to chemiluminescence immunoassay (CLIA) in the country, will also contribute to stimulating the demand of CLIA in the region.

Competitive Landscape

The chemiluminescence immunoassay (CLIA) market is moderately competitive and consists of major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are vigorously making acquisitions and new product launches with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are F. Hoffmann-La Roche AG, Mindray Medical International Limited, Siemens Healthcare GmbH, Beckman Coulter Inc. (Danaher Corporation), and DiaSorin S.p.A.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Chronic Diseases
4.2.2 Increasing Technological Advancements
4.3 Market Restraints
4.3.1 Scarcity of Skilled Labor and Healthcare Professionals
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Analyzers
5.1.1.1 Automated
5.1.1.2 Semi-Automated
5.1.2 Reagents
5.1.2.1 Luminophore Markers
5.1.2.2 Enzymatic Markers
5.1.3 Consumables
5.2 By Application
5.2.1 Oncology
5.2.2 Autoimmune Disorder
5.2.3 Infectious Disease
5.2.4 Cardiovascular Disease
5.2.5 Endocrine Disorders
5.2.6 Others
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Hospital and Clinical Laboratories
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche AG
6.1.2 Mindray Medical International Limited
6.1.3 Siemens Healthcare GmbH
6.1.4 Beckman Coulter Inc. (Danaher Corporation)
6.1.5 DiaSorin S.p.A.
6.1.6 Sysmex Corporation
6.1.7 Randox Laboratories Ltd.
6.1.8 Tosoh Corporation
6.1.9 Shenzhen New Industries Biomedical Engineering Co., Ltd.
6.1.10 BioMerieux

7 MARKET OPPORTUNITIES AND FUTURE TRENDS